Cargando…
Contribution of Cancer-Targeting Drugs toward Faster Clinical Application
Autores principales: | Yoon, Sungpil, Kim, Hyung Sik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224280/ https://www.ncbi.nlm.nih.gov/pubmed/35742888 http://dx.doi.org/10.3390/ijms23126445 |
Ejemplares similares
-
First-Line Combination Treatment with Low-Dose Bipolar Drugs for ABCB1-Overexpressing Drug-Resistant Cancer Populations
por: Yoon, Sungpil, et al.
Publicado: (2023) -
Clinical genomics—but faster
por: McNeill, Alisdair
Publicado: (2021) -
Low-Dose Rifabutin Increases Cytotoxicity in Antimitotic-Drug-Treated Resistant Cancer Cells by Exhibiting Strong P-gp-Inhibitory Activity
por: Lee, Ji Sun, et al.
Publicado: (2022) -
Terconazole, an Azole Antifungal Drug, Increases Cytotoxicity in Antimitotic Drug-Treated Resistant Cancer Cells with Substrate-Specific P-gp Inhibitory Activity
por: Lee, Ji Sun, et al.
Publicado: (2022) -
Running faster. Standing still
por: Darbyshire, Philip
Publicado: (2017)